DNAJB1 and rheumatoid arthritis: There are only few clinical observations that show promising effects of HSP therapy in patients with rheumatoid arthritis (RA) and patients with diabetes type I. The former trial concerned highly conserved bacterial Hsp40-derived peptide (dnaJP1) which was orally administered to 15 patients with early RA.